Rapid research in a deadly epidemic pays off
This week’s US Food and Drug Administration approval of an Ebola drug is a big milestone in drug development — one that’s closely tied to our current efforts to fight COVID-19.
Before COVID-19 started sweeping across the world, Ebola was one of the most high-profile viral diseases on the planet. “Everyone was ready to speed up and contribute and do things with Ebola that they don’t routinely do because Ebola is such a dire situation,” virologist Daniel Bausch told The Verge’s Justine Calma last August. “There are a lot of bad diseases in the world, but there’s not many that provoke the same sort of response and kind of an all-hands-on-deck approach to things.”
More than a year later, and the Ebola experiments have finally paid off in…